Navigation Links
Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

CHICAGO, GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC), ovarian cancer and soft tissue sarcoma (STS). These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.

Pazopanib is an oral, investigational angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit, important proteins in the angiogenic process. Angiogenesis, which is the growth of new blood vessels in the body, plays a critical role in the growth and spread of tumors.

About Renal cell carcinoma study. This ongoing Phase II randomized discontinuation study is evaluating patients with advanced or metastatic RCC who have not received prior systemic therapy or have failed one prior therapy (cytokine or bevacizumab-containing regimen). All patients received 800 mg of pazopanib taken orally, once-daily during a 12 week lead-in period. Based on data available on 60 patients at the time of a planned interim analysis, the Independent Data Monitoring Committee (IDMC) recommended that randomization to placebo for patients with stable disease should be discontinued. The study continued as an open-label, single- arm study with all patients receiving pazopanib.

The preliminary week 12 response rate for all 225 patients was 27%. In addition, stable disease was achieved in 46% of patients for a total disease control rate of 73%. Responses have been observed beyond week 12, and the overall response rate will be reported at study completion. Response was determined according to RECIST (Response Evaluation Criteria In Solid Tumors) which is a set of published rules that defines when cancer patients improve (respond), stay the same (stable), or worsen (progress) during tr
'"/>




Page: 1 2 3 4

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. New Drug Shows Significant Improvement In HIV-related Heart Condition
5. Greek Study Shows Living In The Hills May Be Healthier
6. Research Shows Carbon Monoxide Prevents Inflammations
7. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
8. Novartis MS Drug Shows Promising Results
9. MRI Shows Emotional Changes During Menstrual Cycle
10. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
11. AIDS drug GS 9137 Shows Promise
Post Your Comments:
(Date:7/12/2014)... my mom’s stroke, she loss the use of her right side. ... his left side. Eating became a difficult task for them so ... enjoy eating again,” said an inventor, from Fayetteville, N.C. As a ... (P C H PLATE). , The PATRICIA CAROL HALL PLATE (P ... individuals who suffer from stroke, experience tremors or loss of movement. ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... to move forward in U.S. courts, Bernstein Liebhard LLP ... elevated metal ion levels to the failure of metal-on-metal ... 2nd issue of The Journal of Bone & Joint ... received unilateral Articular Surface Replacement prostheses at least twelve ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 For those who ... bodies can readily absorb the nutrients in food. The enzymes ... that are small enough to be absorbed by human bodies. ... a lack of enzymes in regular food is the cause ... product that was started by Michelle DelPresto, a mother of ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... 2014 As reported in this July ... and Technology), the June 25th, 2014 Supreme Court ruling in ... world. It was also met with both cheers and ... it was seen from an individual privacy perspective, or a ... there is now precedent which will require law enforcement officials ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5
... during college, survey shows , , MONDAY, July 7 (HealthDay ... common before and during college, a new study shows. ... (57.1 percent female) at three urban college campuses to ... , 407 (44.7 percent) of respondents said they experienced ...
... the risk seems bigger if certain painkillers are ... News) -- The widely prescribed class of antidepressants ... in the upper gastrointestinal tract, especially when taken ... study says. , Although reports of this effect ...
... Preserve Vital Stem Cells During, Their Menstrual Flow; Potential for Future Anti-Aging ... ... Fla., July 7 With today,s hectic,lifestyle, where most women are juggling ... a serious illness in,the future is not something that readily comes to ...
... HARRISBURG, Pa., July 7 Need to find ... area? Are you,a senior citizen living in Pennsylvania ... information on oral health topics such as,brushing and ... no,further! PDA,s website, http://www.padental.org, is an ...
... CCA Industries,Inc. (Amex: CAW ) declared today a ... shareholders of record as of August 1, 2008, payable on,September ... 31, 2008 were $17,389,985.,Net income was $790,692 and earnings per ... of $1,292,921 and earnings per,share of $0.18 fully diluted for ...
... In a New York City metro-area first, a 93-year-old ... at NewYork-Presbyterian Hospital, the only center on the Eastern ... new stent graft was implanted under an FDA-approved clinical ... a complex form of abdominal aortic aneurysms in which ...
Cached Medicine News:Health News:Relationship Violence Common Among College Students 2Health News:Popular Antidepressants Linked to GI Bleeding 2Health News:Popular Antidepressants Linked to GI Bleeding 3Health News:Taking Control: Future Therapies for a Host of Serious Diseases May Be Found in Women's Menstrual Blood 2Health News:Pennsylvania Dental Association Website: A Great Resource for Pennsylvania Residents 2Health News:CCA Industries, Inc. Declares Its Seventeenth Consecutive Dividend 2Health News:NYC first: Complex aneurysm treated using new fenestrated endograft stent 2
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
... Combines BchiVac V-500 with Vacuum Controller V-800 ... mechanism turns V-500 on and off as needed to ... is a powerful PTFE membrane vacuum pump designed to ... suited for use with up to two rotary evaporators ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
... a new addition to the powerful PTFE membrane ... pump can achieve an ultimate vacuum of 1 ... Applications For use with vacuum ... Distillation applications from lab size up to industrial ...
Medicine Products: